Nisa Investment Advisors LLC Purchases 11,530 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Nisa Investment Advisors LLC grew its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 38,433.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,560 shares of the company’s stock after buying an additional 11,530 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Design Therapeutics were worth $31,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in Design Therapeutics during the third quarter worth $47,000. Corton Capital Inc. boosted its holdings in shares of Design Therapeutics by 56.6% in the 3rd quarter. Corton Capital Inc. now owns 27,134 shares of the company’s stock worth $64,000 after buying an additional 9,811 shares during the last quarter. Algert Global LLC grew its position in Design Therapeutics by 83.3% during the third quarter. Algert Global LLC now owns 35,620 shares of the company’s stock valued at $84,000 after buying an additional 16,190 shares during the period. Jump Financial LLC grew its position in shares of Design Therapeutics by 284.7% during the 3rd quarter. Jump Financial LLC now owns 46,700 shares of the company’s stock valued at $110,000 after acquiring an additional 34,561 shares during the period. Finally, Barclays PLC increased its stake in shares of Design Therapeutics by 353.1% during the 3rd quarter. Barclays PLC now owns 71,678 shares of the company’s stock worth $170,000 after purchasing an additional 55,858 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wedbush reissued a “neutral” rating and set a $5.00 price objective on shares of Design Therapeutics in a report on Wednesday, March 20th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price objective on shares of Design Therapeutics in a research note on Wednesday, March 20th. Seven analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $5.50.

Design Therapeutics Stock Up 5.1 %

Shares of DSGN opened at $3.89 on Tuesday. The business’s 50-day moving average price is $3.20 and its 200-day moving average price is $2.64. Design Therapeutics, Inc. has a twelve month low of $1.94 and a twelve month high of $8.47. The stock has a market cap of $219.76 million, a PE ratio of -3.24 and a beta of 1.82.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Tuesday, March 19th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.11. Analysts expect that Design Therapeutics, Inc. will post -1.25 earnings per share for the current fiscal year.

Insider Activity at Design Therapeutics

In other Design Therapeutics news, Director John P. Schmid bought 17,809 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were acquired at an average cost of $3.74 per share, for a total transaction of $66,605.66. Following the purchase, the director now directly owns 26,965 shares of the company’s stock, valued at $100,849.10. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. In other Design Therapeutics news, Director John P. Schmid acquired 17,809 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now owns 26,965 shares of the company’s stock, valued at $100,849.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director John P. Schmid bought 9,156 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was bought at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the purchase, the director now directly owns 9,156 shares of the company’s stock, valued at $33,144.72. The disclosure for this purchase can be found here. 27.80% of the stock is owned by corporate insiders.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.